Literature DB >> 8047848

Short-term kinetics of the humoral anti-C1q response in SLE using the ELISPOT method: fast decline in production in response to steroids.

J Rönnelid1, Y H Huang, T Norrlander, S Rogberg, B Nilsson, R Gustafsson, L Klareskog.   

Abstract

Twenty four systemic lupus erythaematosus patients and 17 patients with other diagnoses were investigated regarding the presence of cells producing C1q reactive antibodies in peripheral blood mononuclear cells using the ELISPOT technique. These results were then compared with parallel serum levels of C1q reactive antibodies. Current production of anti-C1q was almost entirely confined to the systemic lupus erythaematosus group. Longitudinal analysis of anti-C1q ELISPOT positive patients showed rapid changes in the number of anti-C1q producing cells, but only slowly changing serum levels of the corresponding antibodies in response to glucocorticoids. In one systemic lupus erythaematosus patient prednisolone treatment had a selective effect on this autoantibody production, as the production of anti-C1q spot forming cells rapidly dropped to zero, at the same time as the number of total spot-forming cells showed only less change. In another patient, self-limiting connective tissue disease was associated with temporal occurrence of IgM anti-C1q. We believe, from these data, that the ELISPOT method for determination of current antibody production may be of particular value in longitudinal evaluation of disease course and therapeutic effects in systemic lupus erythaematosus and other rheumatic diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8047848     DOI: 10.1111/j.1365-3083.1994.tb03457.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

1.  Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis.

Authors:  Zhu Chen; Guo-Sheng Wang; Gui-Hong Wang; Xiang-Pei Li
Journal:  Clin Rheumatol       Date:  2012-06-14       Impact factor: 2.980

2.  Defective prevention of immune precipitation in autoimmune diseases is independent of C4A*Q0.

Authors:  G J Arason; R Kolka; A B Hreidarsson; H Gudjonsson; P M Schneider; L Fry; A Arnason
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

3.  Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE.

Authors:  J Rönnelid; A Tejde; L Mathsson; K Nilsson-Ekdahl; B Nilsson
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

Review 4.  Antibodies against C1q in patients with systemic lupus erythematosus.

Authors:  Marten Trendelenburg
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

5.  Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism.

Authors:  Y H Huang; L Schäfer-Elinder; R Wu; H E Claesson; J Frostegård
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

6.  Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.

Authors:  N Marto; M L Bertolaccini; E Calabuig; G R V Hughes; M A Khamashta
Journal:  Ann Rheum Dis       Date:  2004-07-29       Impact factor: 19.103

Review 7.  Detection of autoantibodies in a point-of-care rheumatology setting.

Authors:  Konstantin N Konstantinov; Antonios Tzamaloukas; Robert L Rubin
Journal:  Auto Immun Highlights       Date:  2013-05-18

Review 8.  Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.

Authors:  Virender Kumar; Xiaofei Xin; Jingyi Ma; Chalet Tan; Natalia Osna; Ram I Mahato
Journal:  Adv Drug Deliv Rev       Date:  2021-07-24       Impact factor: 17.873

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.